RA Capital Healthcare Fund LP's Form 4 filing
Boundless Bio, Inc. (BOLD) · filed Apr 4, 2024
- Accession no.
- 0001415889-24-010278
- Filed
- Apr 4, 2024, 4:15 PM ET
- Trade date
- Apr 2, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | 10% Owner |
| Kolchinsky PeterCIK 0001384859 | 10% Owner |
| Shah Rajeev M.CIK 0001619841 | 10% Owner |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 2, 2024 | Common Stock | CConversionAcquired | +1,587,912 | –F1 | – | 1,587,912 | Indirect | |
| Apr 2, 2024 | Common Stock | PPurchaseAcquired | +296,875 | $16.00 | +$4,750,000 | 1,884,787 | Indirect | |
| Apr 2, 2024 | Common Stock | CConversionAcquired | +280,219 | –F1 | – | 280,219 | Indirect | |
| Apr 2, 2024 | Common Stock | PPurchaseAcquired | +15,625 | $16.00 | +$250,000 | 295,844 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 2, 2024 | Common Stock | CConversionDisposed | −871,794 | $0.00 | $0 | 0 | Indirect | |
| Apr 2, 2024 | Common Stock | CConversionDisposed | −153,846 | $0.00 | $0 | 0 | Indirect | |
| Apr 2, 2024 | Common Stock | CConversionDisposed | −716,118 | $0.00 | $0 | 0 | Indirect | |
| Apr 2, 2024 | Common Stock | CConversionDisposed | −126,373 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I.